AGA Medical Pursues Stroke, Migraine Indications And $200 Mil. IPO
This article was originally published in The Gray Sheet
Executive Summary
AGA Medical hopes to complete a pivotal U.S. trial by year-end assessing its Amplatzer PFO Occluder for prevention of recurrent cryptogenic strokes, the company says in a June 20 prospectus for a planned initial public offering worth up to $200 million